-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Nektar Therapeutics, Raises Price Target to $123

Benzinga·03/16/2026 16:37:48
Listen to the news
Citigroup analyst Samantha Semenkow maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises the price target from $102 to $123.